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Anticoagulation in Atrial 
Fibrillation Patients
Peter Magnusson, Joseph V. Pergolizzi Jr, Randall K. Wolf, 
Morten Lamberts and Jo Ann LeQuang
Abstract
Atrial fibrillation (AF) is the most common arrhythmia and may cause thrombo-
embolic events, typically stroke. Advances in pharmacological approaches to antico-
agulation and groundbreaking large randomized controlled trials of non-vitamin K 
antagonist oral anticoagulants (NOACs) have changed the paradigm of anticoagula-
tion therapy. Furthermore, observational studies support the efficacy and safety 
of NOAC. Few studies address the differences among NOACs, but prescriptions 
should be based on a thorough understanding of their pharmacological differences, 
including interactions, side effects, reversibility, and practical approach. In a subset 
of patients with AF, warfarin may still be the preferable option. Consequently, an 
individualized approach to oral anticoagulation is crucial.
Keywords: anticoagulation, apixaban, atrial fibrillation, dabigatran, edoxaban, 
rivaroxaban, vitamin K antagonist, warfarin
1. Introduction: the changing paradigm for anticoagulation
Atrial fibrillation (AF) is a prevalent arrhythmia possessing a well-known 
association with thromboembolic events, especially stroke. In AF, atrial pumping 
ends, and blood tends to pool in the left atrium rather than be pumped into the left 
ventricle. Thrombi can form in the sluggish blood pool in the atrial region known 
as the left atrial appendage (LAA). A typical LAA thrombus can cause stroke or 
peripheral embolism should it break free. Indeed, AF-related strokes tend to be 
more life-threatening than strokes caused by other reasons [1].
Anticoagulation therapy prevents strokes and warfarin; the most commonly 
used vitamin K antagonist (VKA) has been the standard agent used to reduce stroke 
risk in certain AF patients with risk factors since the 1950s [2]. Historically, warfa-
rin has been the drug of choice, but it has often been underused due to its narrow 
risk-benefit interval and the need for frequent monitoring. It is being gradually 
eclipsed by a variety of non-vitamin-K antagonist oral anticoagulants (NOACs) that 
are demonstrating excellent safety and effectiveness without the need for frequent 
monitoring and subsequent dose adjustment.
The availability of several pharmacological approaches to anticoagulation as well 
as a more thorough understanding of risk factors for embolization and bleeding has 
improved patient care but also complicated prescribing choices. The paradigm for 
anticoagulation in AF patients has changed. In addition, there are now options for 
patients that suffer from AF but who, for one reason or another, are unable to take 
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anticoagulants. These patients can often undergo closure of the LAA, the site of the 
majority of the thrombi.
2. Valvular vs. nonvalvular atrial fibrillation
The distinction between valvular and nonvalvular AF is not helpful in terms of 
defining the nature of the arrhythmia, but it may be of value in better defining the 
patient’s risk for thromboembolism and which type of anticoagulation therapy (if 
any) is indicated [3]. AF may be paroxysmal or persistent, for example, or symp-
tomatic or asymptomatic (“silent”). When decisions concerning anticoagulation 
are to be reached, the main factors that may affect prescribing choices are valvular 
versus nonvalvular forms of AF. Moreover, it should be noted that patients with 
nonvalvular AF may have concomitant valvular heart disease.
2.1 Nonvalvular AF
In 2016, the European Society of Cardiology (ESC) defined nonvalvular AF 
as an exclusion of moderate to severe mitral valve stenosis or metallic prosthetic 
heart valves [4]. The American Heart Association (AHA) and American College of 
Cardiology (ACC) went a bit further in the exclusion and stated nonvalvular AF 
was AF not associated with rheumatic mitral stenosis, metallic or bioprosthetic 
heart valves, or mitral valve repair [5]. It has even been stated by experts that 
perhaps the terms “nonvalvular” and “valvular” AF are outmoded and no longer 
useful. See Table 1.
Anticoagulation therapy helps to mitigate the risk of stroke in patients with 
nonvalvular forms of AF [14]. As such, anticoagulation may be indicated for 
patients with nonvalvular AF, but other factors may come into play. Surgery can 
affect the anticoagulation decision, both in terms of whether the AF patient needs 
anticoagulation therapy before and after surgery or just perioperatively for a short 
window of time [6].
2.2 Valvular AF
As seen in Table 1, valvular heart disease encompasses such conditions as mitral 
stenosis, mitral regurgitation, aortic stenosis, and aortic insufficiency. Valvular 
heart disease has an age-dependent prevalence of about 0.7% for 18–44-year-olds 
and 13.3% in patients ≥75 years, and it is considered a risk factor for stroke and 
systemic embolism. Valvular heart disease may coexist with arrhythmias, including 
AF [15]. Prosthetic heart valves are associated with thrombin growth, and heart 
valve surgery may expose the blood pool to mechanical hardware, both of which 
may activate intrinsic coagulation pathways. Valvular AF has been associated with 
platelet activation, which may contribute to further thromboembolic risk [3]. Since 
patients with mechanical heart valves were considered to be at risk for thromboem-
bolism, they should always be prescribed with VKA for anticoagulation as no data 
exist for the use of NOAC in this subgroup [13]. Distinguishing characteristics for 
valvular and nonvalvular heart diseases appear in Table 2.
2.3 Other patient populations
AF is a prevalent condition and occurs in many patient subpopulations that 
merit a short discussion in terms of anticoagulation and AF classification.
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2.3.1 Transcatheter aortic valve procedures
Transcatheter aortic valve replacement (TAVR) is often recommended for 
low-risk patients with severe symptomatic aortic stenosis, but less is elucidated 
about the role of postsurgical anticoagulation therapy in this population [16]. 
TAVR candidates have a 40% rate of pre-existing AF and a further 10% chance of 
developing new-onset AF following TAVR [17]. Most patients discharged follow-
ing TAVR (n = 16,694) are on dual antiplatelet therapy without anticoagulation 
(81.1%) [18].
Society or source Definition of valvular AF Definition of nonvalvular AF
American College of 
Cardiology Expert 
Consensus 2017 [6]
AF associated with rheumatic mitral 
stenosis, a mechanical or bioprosthetic 
heart valve, or mitral valve repair
All AF not associated with 
rheumatic mitral stenosis, a 
mechanical or bioprosthetic 
heart valve, or mitral valve 
repair
American College of Chest 
Physicians 2018 [7]
Moderate to severe mitral stenosis or 
mechanical heart valve
AF not associated with 
moderate to severe mitral 
stenosis or mechanical heart 
valve
Canadian Cardiovascular 
Society 2016 [8]
Rheumatic mitral stenosis, mitral 
valve repair, mechanical or 
bioprosthetic heart valve
AF not associated with 
mitral stenosis, mitral valve 
repair, and mechanical or 
bioprosthetic heart valve
Canadian Cardiovascular 
Society 2018 [9]
Rheumatic mitral stenosis, moderate 
to severe non-rheumatic mitral 
stenosis, or mechanical heart valve
AF not associated with 
rheumatic mitral stenosis, 
moderate to severe non-
rheumatic mitral stenosis, or 
mechanical heart valve
De Caterina, Camm (Expert 
Opinion) 2016 [10]
Proposes the use of “mechanical and 
rheumatic mitral AF” or MARM-AF 
as alternative
AF not associated with 
mechanical and rheumatic 
mitral AF
European Heart Rhythm 
Association and European 
Society of Cardiology 
Working Group on 
Thrombosis 2017 [11]
The term is outdated and should be replaced by a functional Evaluated 
Heartvalves, Rheumatic or Artificial (EHRA) category, based on the 
anticoagulation therapy used. EHRA typically is described as Types 1 and 2
Type 1 is valvular heart disease requiring VKA anticoagulation
Type 2 is valvular heart disease requiring VKA or NOAC therapy
European Society of 
Cardiology 2016 [4]
Avoids the term, preferring “AF 
related to hemodynamically 
significant mitral stenosis or 
prosthetic mechanical heart valves”
AF not related to 
hemodynamically significant 
mitral stenosis or prosthetic 
mechanical heart valves
National Heart Foundation 
of Australia/Cardiac Society 
of Australia and New 
Zealand 2018 [12]
Moderate to severe mitral stenosis or 
mechanical heart valve
AF not associated with 
moderate to severe mitral 
stenosis or mechanical heart 
valve
UMBRIA-Fibrillazione 
Atriale Study (Clinical 
Trial) 2019 [13]
Favors the term Type 2 valvular 
heart disease, defined as moderate to 
severe mitral or aortic regurgitation, 
moderate to severe aortic stenosis, 
or mild mitral stenosis (mitral valve 
areas >2.0 cm2 on echocardiography)
AF not associated with 
moderate to severe mitral or 
aortic regurgitation, moderate 
to severe aortic stenosis, or mild 
mitral stenosis
Table 1. 
The definitions for nonvalvular and valvular AF, which can be crucial to selecting appropriate anticoagulation 
therapy, are blurred and may even be outmoded. Note that some guidelines did not define these terms at all.
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In a study of 172 patients who underwent TAVR plus a pacemaker implant, 25% 
of the patients developed new-onset AF or atrial flutter over the median follow-up 
period of 15 months. Of these patients, 14.7% had at least an episode of asymptom-
atic AF, which was detected by device diagnostics in the pacemaker but not on their 
electrocardiogram (ECG). The cumulative incidence of stroke in this population 
was 1.4% for patients in normal sinus rhythm compared to 12.5% for new-onset 
AF patients. Patients with obvious AF, detected on ECG, were significantly more 
likely to be given anticoagulation therapy than those with subclinical new-onset AF 
(70% vs. 15%, respectively, p = 0.02) [19]. The rate and characteristics of AF in this 
particular patient population as well as those with new transcatheter aortic valve 
implantation (TAVI) are not extensively studied.
2.3.2 Catheter ablation patients
Patients undergoing catheter ablation for AF typically receive perioperative anti-
coagulation treatment that is discontinued following surgery providing they have 
no other risk factors. In the Role of Coumadin in Preventing Thromboembolism in 
AF Patients Undergoing Catheter Ablation (COMPARE) study, it was shown that 
continuing warfarin for 48 hours after the procedure was associated with fewer 
periprocedural strokes and fewer minor bleeding events compared to bridging 
using low-molecular-weight heparin [20].
Results are mixed in terms of the safety and effectiveness of warfarin versus 
newer agents. In a prospective cohort of 290 AF ablation patients, periprocedural 
administration of dabigatran compared to warfarin was associated with a higher 
rate of thromboembolic events (2.1% vs. 0.0% for dabigatran and warfarin, respec-
tively) and major bleeding complications (6% vs. 1%, p = 0.019) [21]. However, in 
a case-control analysis of 763 patients undergoing radio-frequency AF ablation, 
dabigatran patients had similar anticoagulation effectiveness and safety compared 
to warfarin patients [22]. A meta-analysis of 14 studies on the use of dabigatran vs. 
warfarin for periprocedural anticoagulation in patients undergoing catheter abla-
tion for AF (n = 4782) reported dabigatran patients had a similar incidence of major 
bleeding events and thromboembolic events compared to warfarin patients, and 
both agents were associated overall with low rates of complications [23].
Aspects of heart 
disease
Valvular 
heart 
disease 
Type 1
Valvular 
heart 
disease 
Type 2
Nonvalvular 
AF
Comments
Aortic regurgitation Yes
Aortic stenosis Yes High risk for stroke
Mechanical heart 
valve
Yes High risk for thromboembolism
Mild mitral stenosis Yes
Mitral regurgitation Yes Common form of valvular heart 
disease
Moderate to severe 
aortic stenosis
Yes
Moderate to severe 
mitral stenosis
Yes May be of rheumatic origin
Table 2. 
An overview of distinguishing characteristics for valvular heart disease (Types 1 and 2) versus nonvalvular 
heart disease [13].
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NOACs have been evaluated in patients undergoing catheter ablation for 
AF. In the RE-CIRCUIT, it was shown that uninterrupted dabigatran is associ-
ated with fewer bleeding complications than uninterrupted warfarin in this 
population [24]. The AXAFA-NET 5 trial found that continuous apixaban is 
safe and effective following catheter ablation to treat AF in terms of bleeding, 
stroke, and cognitive function [25]. Uninterrupted rivaroxaban was shown to 
be feasible in this population with event rates similar to that of uninterrupted 
VKA [26].
2.3.3 Cardiac implantable electronic device patients
In some cases, patients on anticoagulation therapy are subsequently indicated 
for implantation of a cardiac implantable electronic device (CIED). In a random-
ized study of patients undergoing implantation of an implantable cardioverter 
defibrillator (ICD), 343 patients were randomized either to undergo bridging to 
heparin during the procedure or to be continued on warfarin. Major thromboem-
bolic complications in this study were rare and similar between groups (the heparin 
patients reported one case of cardiac tamponade and one case of myocardial infarc-
tion, while the warfarin group had one transient ischemic attack). Device pocket 
hematoma of clinical significance occurred in 3.5% of warfarin patients compared 
to 16.0% of heparin patients [27].
2.3.4 Clinically silent AF
The prevalence of asymptomatic or “clinically silent” (subclinical) AF is 
unknown but likely substantial [28]. Clinically silent AF is often captured by device 
diagnostics in CIED patients. In a study of dual-chamber pacemaker patients 
(411 without known AF and 267 with known AF), it was found that at a median 
38 months of follow-up, 30% of those without known AF had silent AF verifi-
able by the pacemaker. Risk factors for silent AF in this study were heart failure 
(p = 0.03) and age > 75 years (p = 0.0002). Sixty-two percent of patients who devel-
oped silent AF (n = 125) were administered with anticoagulation therapy; of those 
with known AF at implant (n = 216), 80% took anticoagulation therapy. The annual 
rate of stroke was 1.9% for patients who developed silent AF postimplant compared 
to 2.1% for those with known AF at implant. Vascular dementia developed in 11.2% 
of those with known AF at implant compared to 6.2% of those who developed silent 
AF postimplant (p = 0.048) [29].
2.3.5 Clinically silent stroke
Silent stroke may be defined as asymptomatic cerebral infarction, which is typi-
cally discovered when brain lesions are found during imaging procedures. Indeed, 
silent stroke is one of the most common incidental findings in brain scans [30]. 
The incidence and prevalence of this condition is not known nor are risk factors, 
although it appears that patients with AF are at elevated risk compared to those 
without this arrhythmia [31, 32]. The role of anticoagulation for patients at risk for 
silent stroke is not clear [30].
3. Risk stratification for thrombosis
The goal of anticoagulation therapy in AF patients is to reduce their risk 
for stroke or systemic embolism. The CHA2DS2-VASc scoring system has been 
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developed to calculate the numerous factors that may increase the likelihood 
of thrombus: hypertension, heart failure, older age, diabetes, stroke, transient 
ischemic attack, vascular disease, and female sex [5, 33]. For patients who 
score ≥ 1 on this scoring metric, oral anticoagulation therapy is preferred over 
antiplatelet therapy. However, scoring tools are imperfect. A large retrospective 
review of 140,420 AF patients found the annual rate for ischemic stroke with 
those scoring ≤1 was lower than previously stated (0.1–0.2% for women and 
0.5–0.7% for men) [33]. A retrospective cohort study found that age between 
65 and 74 years was a stronger predictor of stroke compared to the other items 
on the CHA2DS2-VASc scoring system. People in that age bracket had an annual 
stroke risk of 1.78%. By the same token, AF patients <50 years of age had low risk 
(0.53%) [34].
4. Safety issues and bleeding risks
Hemostatic alteration introduces the risk of potentially devastating bleeding, 
typically intracranial hemorrhage [35]. The consequences of a bleeding event are of 
greater clinical importance than the amount of bleeding itself, for instance, a small 
amount of pericardial bleeding following cardiac surgery may have potentially 
life-threatening consequences, while a much larger bleeding event may be clini-
cally manageable. Bleeding is a high-risk situation and is not the subject of clinical 
trials. In fact, most of the evidence about bleeding rates and risks is derived from 
safety reports in clinical trials. Thus, expert consensus often overrides data-driven 
evidence in terms of bleeding risks.
In addition to procedure-related bleeding risks, individual patient factors for 
bleeding must also be taken into account. The HAS-BLED score, based on a survey 
of almost 4000 patients in the Euro Heart Survey on AF, offers a way to create a 
numerical score based on several factors. The acronym encapsulates some of the 
key risks: hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio, elderly (>65 years), and drugs 
and/or alcohol concomitantly [36]. The HAS-BLED has seen a wide adoption, but 
two important points must be considered. Firstly, many risk factors in the HAS-
BLED score are shared with other risk-scoring schemes for calculating the risk of 
thrombosis, e.g., hypertension and stroke. Secondly, a high HAS-BLED score is not 
necessarily indicative that oral anticoagulation should be omitted but may be used 
to select patients in need for regular follow-up.
5. Drug therapies and prescribing options
For over half a century, the anticoagulation regimen for AF was the use of VKA, 
also called coumarins. They included acenocoumarol, phenprocoumon, fluindione, 
and warfarin [37]. Warfarin is by far the most common of these and is the most 
commonly used anticoagulant [38]. These are effective agents, but they have certain 
disadvantages: a narrow therapeutic range, required laboratory monitoring, good 
patient adherence for safety and effectiveness, and certain risks for drug-drug and 
drug-food interactions [39].
The emergence of NOAC drugs has changed the paradigm for anticoagulation 
therapy. These agents have been shown noninferior to warfarin with respect to 
thromboembolism. They may alleviate some of the disadvantages of VKA anti-
coagulation, but some of them do not have reversal agents. A short summary of 
anticoagulants appears in Table 3.
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Apixaban Dabigatran Edoxaban Rivaroxaban Warfarin
Dosing 5 mg × 2 but 2.5 mg × 2 if two 
of the following: age > 80 years, 
weight < 60 kg, or creatinine 
>133 μmol/l
150 mg × 2 or 110 mg × 2 if either: 
age > 80 h, GFR 30–50 ml/min, 
GI disease, increased risk of 
bleeding
60 mg × 1 but 30 × 1 if one of 
the following: weight ≤ 60 kg, 
concomitant ciclosporin, dronedarone, 
erythromycin, ketoconazole
20 mg × 1 but 15 mg 
× 1 if GFR 15–50 ml/
min
Strat dose 5–7.5 mg, 
daily, and then 
adjustment to INR
Renal failure Contraindicated Contraindicated Contraindicated Contraindicated Approved indication
Risk of 
intracranial 
bleeding vs. 
warfarin
Lower Lower Lower Lower —
Interactions with 
other drugs or 
food
Few Few but note dronedarone Few Few Numerous
Possible to crush 
tablet
Yes No Yes Yes Yes
Independent of 
timing of food 
intake
Yes Yes Yes No Yes
Laboratory 
follow-up
6–12 months 6–12 months 6–12 months 6–12 months Frequent, typically 
1–2 every month
Specific antidote No Yes, instant effect No No Yes, slow effect
Table 3. 
A short summary of anticoagulation agents.
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5.1 Vitamin K antagonists
Vitamin K antagonists (VKA) act by reducing the synthesis of the coagulation 
factors that rely on vitamin K. They inhibit the liver’s ability to synthesize the 
precursors to clotting factors, Factor II (prothrombin), Factor VII, Factor IX, and 
Factor X. For that reason, it may take up to 2 weeks before all of these factors are 
eliminated and the drug is effective [35]. Warfarin may be reversed with oral or 
intravenous vitamin K, although the reversal may take hours to take effect [40]. 
Warfarin is an effective anticoagulant as long as blood concentrations fall within 
a relatively narrow therapeutic range; regular monitoring for time in therapeutic 
range is required. There is a wealth of clinical experience with VKA to inform 
prescribing choices.
Although warfarin may seem to be eclipsed by newer and more convenient 
agents, warfarin is still frequently prescribed and may be the optimal choice for 
some patients. VKA anticoagulation therapy decreases the risk of ischemic stroke in 
AF patients by >60%, although it does present a slightly increased risk for bleeding 
(<0.3%/year) [41].
Prescribing considerations for warfarin must include its narrow therapeutic 
index (overdosing may cause bleeding, and underdosing may cause thrombosis). 
Thus, warfarin patients must be followed with regular assessment of their interna-
tional normalized ratio (INR). While genetics influence how an individual responds 
to VKA, such tests are not often used, and there is little guidance in terms of how to 
apply the findings from such genetic tests to therapeutic choices [42, 43]. Warfarin 
can be monitored at home with a home-based system and weekly test strips. The 
direct cost of warfarin is lower than for NOAC medications.
An important safety concern about warfarin involves hemorrhagic stroke which 
may occur in patients on VKA therapy. In fact, about 12–14% of cases of intrace-
rebral hemorrhage are associated with warfarin [44]. VKA agents appear to con-
tribute to vascular calcification to a greater extent than NOACs [45]. Drug-drug or 
food-drug interactions often occur with VKA therapy, particularly involving foods 
and drugs that induce or inhibit the CYP 450 enzymes [39, 46].
5.2 Non-vitamin-K antagonist oral anticoagulants (NOACs)
Four NOAC medications are approved and indicated for stroke prevention in 
patients with nonvalvular AF in the USA with some international variations. The 
NOAC category offers drugs in two classes: those that inhibit Factor Xa (apixaban, 
edoxaban, rivaroxaban) and direct thrombin inhibitors (dabigatran). Trials have 
demonstrated they are effective anticoagulation options with reasonable safety 
profiles. The advantages of NOACs compared to VKA therapy include predictable 
pharmacokinetics, rapid onset and offset of action, recent promising evidence from 
clinical trials showing reductions in stroke, intracranial hemorrhage, and all-cause 
mortality [46]. NOACs offer advantages, but the lingering concern with such medi-
cations is the lack of a reversal agent to stop the anticoagulatory effect in the event 
of a bleeding emergency for all these agents except dabigatran. The monoclonal 
antibody idarucizumab is available as a specific, with rapid onset, reversal agent for 
dabigatran [47].
5.2.1 Apixaban
Apixaban is a highly selective direct inhibitor of activated coagulation Factor 
X that can indirectly inhibit thrombin-induced platelet aggregation. It is an oral 
anticoagulant with linear and predictable pharmacokinetics and rapid onset/offset 
9Anticoagulation in Atrial Fibrillation Patients
DOI: http://dx.doi.org/10.5772/intechopen.88965
of action and has relatively few potential drug-drug or drug-food interactions [48]. 
In a meta-analysis of 16 studies, apixaban was more effective in reducing the rate of 
thromboembolic events compared to warfarin but similar to warfarin in reducing 
the risk of stroke [49]. However, it may reflect patient selection, and it is important 
to stress that no head-to-head studies with a randomized controlled have been 
conducted.
A post hoc analysis of the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study compared 
clinical characteristics and outcomes in AF patients with a history of cancer taking 
either apixaban or warfarin. The outcomes were stroke, systemic embolism, major 
bleeding, and mortality [50]. In the study, 157 patients had active cancer, the 
remaining 1079 had remote cancer, and they were compared to 16,947 patients 
without cancer. No significant relationships between cancer and stroke, systemic 
embolism, ischemic stroke, or death could be determined, and the relationship 
between cancer and myocardial infarction was not significant after statistical 
adjustment. Apixaban was associated with improved rates of the composite 
endpoint (stroke, systemic embolism, myocardial infarction, and mortality) in 
those with active cancer and in those without cancer but not in those with remote 
cancer [50]. In a post hoc analysis of the ARISTOTLE study, 76.5% of patients were 
found to be on polypharmacy, defined as ≥5 or more drugs, and mortality, stroke, 
and systemic embolism rates increased with the greater number of concomitant 
medications [51]. Apixaban was deemed to be more effective than warfarin in 
AF patients on polypharmacy compared to warfarin and at least equivalent in 
terms of safety. An analysis of ARISTOTLE study data found 104 patients had a 
bioprosthetic heart valve replacement, and 52 had undergone valve repair. The 
safety and effectiveness of apixaban in this subpopulation was consistent with the 
larger study results, that is, apixaban may be an appropriate choice for a patient 
with valve replacement or repair [52]. Using data from this study, it was found that 
30.5% of patients were taking potentially interacting medications at the time of the 
study (2722 apixaban and 2824 warfarin patients), which is common among AF 
patients. For the primary outcome endpoint (stroke or systemic embolism), both 
apixaban and warfarin were similar, and interacting medications had no effect 
on this outcome [53]. Apixaban results were also consistent in the multimorbid 
population (64% of ARISTOTLE population, defined as ≥3 comorbid conditions); 
apixaban was similarly effective in the general ARISTOTLE population as in the 
multimorbid subpopulations, including those with high multimorbidity (≥6 
comorbid conditions) [54].
Using a Markov model and a population model from 2017 to 2030, apixaban 
was compared to warfarin in the German population of nonvalvular AF patients. 
The study showed that apixaban use instead of a VKA could avoid 52,185 major 
clinical events, including 14,319 all-cause deaths and 15,383 nonfatal strokes [55]. A 
Department of Defense study in the USA (n = 41,001) found apixaban was associ-
ated with a significantly lower risk of stroke, systemic embolism, or major bleeding 
compared to warfarin and to rivaroxaban [56].
5.2.2 Dabigatran
Dabigatran, a prodrug, is a direct thrombin inhibitor with predictable pharma-
cokinetics and pharmacodynamics, no need for laboratory monitoring, and fewer 
drug-food and drug-drug interactions compared to VKA. Unlike other NOAC 
drugs, dabigatran has an approved specific reversal agent, idarucizumab [57]. 
Dabigatran holds the distinction of being the first NOAC agent to be approved for 
nonvalvular AF patients [58].
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The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) 
study (n = 18,113) compared dabigatran at two doses (150 or 110 mg twice a day) 
to warfarin in a trial of AF patients that excluded those with mechanical heart 
valves, moderate to severe mitral stenosis, or valvular heart disease requiring 
intervention (patients with valvular heart disease not requiring intervention could 
be included) [59]. For dabigatran 150 mg twice daily, the rate of stroke or systemic 
embolic events was significantly lower than that of patients taking warfarin, 
but for those on 110 mg twice daily, rates were similar to warfarin. Intracranial 
bleed rates and mortality rates were significantly lower in both dabigatran groups 
compared to warfarin regardless of whether or not the patient had valvular heart 
disease [59].
The randomized phase II study to evaluate the safety and pharmacokinetics of 
oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN) 
study was terminated early when it compared VKA therapy to dabigatran and 
the dabigatran group experienced a high rate of thromboembolic and bleeding 
adverse events [60]. The study enrolled patients undergoing atrial and/or mitral 
mechanical valve implantation who were administered with 150 or 300 mg of 
dabigatran twice a day to determine relative safety and effectiveness of dabiga-
tran compared to warfarin [61]. Dabigatran patients experienced higher rates of 
adverse events: 5% had strokes, 2% transient ischemic attacks, and 2% myocardial 
infarction compared to only transient ischemic attacks only at a rate of 2% in the 
warfarin group. The reasons for this have been speculated: dabigatran doses were 
too high, dabigatran was introduced too soon after valve surgery, or there remain 
factors to be elucidated about thromboembolic risks associated with artificial 
heart valves [62].
5.2.3 Edoxaban
Edoxaban, a factor Xa inhibitor, is approved for the prevention of stroke in 
nonvalvular AF patients. Factor Xa is a protease that serves to convert prothrombin 
into thrombin which, in turn, converts fibrinogen into fibrin and allows for clot-
ting. Edoxaban has a dual mechanism of action in that it inhibits both free Factor 
Xa and also the by-product Factor Xa produced by prothrombinase [63]. Like other 
NOAC medications, it requires less laboratory monitoring, has fewer drug-drug 
and food-drug interactions, and lowers the risk of major bleeding compared to 
warfarin. It is not metabolized via the CYP450 enzyme system (which is the case 
for apixaban and rivaroxaban), and it was shown in the ENGAGE AF-TIMI study 
to be noninferior to warfarin. It is an oral agent that need be taken only once daily 
[63]. The safety and efficacy of edoxaban seem to be similar to other NOAC medi-
cations for the control of venous thromboembolism to reduce the risk of stroke in 
nonvalvular AF patients.
The Effective Anticoagulation with Factor Xa Next Generation in Atrial 
Fibrillation-Thrombosis in Myocardial Infarction 48 study (ENGAGE-AF-TIMI 48) 
compared edoxaban to warfarin in AF patients with and without valvular heart 
disease [64]. Valvular heart disease is associated with an increased risk for major 
adverse cardiovascular events, major bleeding, and death. Higher-dose edoxaban 
was found to be similarly effective to warfarin for all endpoints (stroke, systemic 
embolic event, major bleeding) in a trial of 18,222 patients [64].
A substudy of ENGAGE AF-TIMI 48 examined the effect of patient age on 
bleeding risk (risk is greater with older age) and favored edoxaban over warfarin 
for AF patients ≥75 years [65]. As such, edoxaban may be preferred over warfarin in 
elderly patients at risk for falls [66].
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5.2.4 Rivaroxaban
Rivaroxaban is an NOAC that acts as a selective, direct inhibitor of activated 
coagulation Factor Xa. It is an oral medication with a rapid onset/offset of action 
and short half-life. It does not require laboratory monitoring and has predict-
able pharmacokinetics and pharmacodynamics and relatively few drug-drug and 
drug-food interactions compared to warfarin [67]. There is currently no approved 
reversal agent for rivaroxaban.
The ROCKET-AF study (n = 14,264) compared rivaroxaban to warfarin and 
found rivaroxaban had a 1.7% risk of stroke or systemic embolism at 1 year com-
pared to 2.2% for warfarin. The composite safety endpoint was major bleeding or 
major bleeding plus clinically relevant non-major bleeding and occurred at a rate of 
14.9% for rivaroxaban and 14.5% for warfarin patients [68]. The study concluded 
that rivaroxaban was noninferior to warfarin in prevention of stroke and systemic 
embolism. There was no significant difference in major or non-major but clinically 
relevant bleeding between rivaroxaban and warfarin. Gastrointestinal bleeding 
occurred more often in rivaroxaban than warfarin patients, but rates of major 
bleeding were similar.
5.3 Rotation of anticoagulation
There may be cases when it becomes necessary to change from warfarin to an 
NOAC or vice versa. In the case of moving from VKA to an NOAC, INR monitoring 
is needed throughout the shift [14]. The opposite transition, from NOAC to VKA, 
may require bridging to heparin or starting off with a lower dose of the NOAC 
medication at first, INR twice a week (minimum), and adjustment of VKA until the 
INR reaches ≤2.0 [69].
5.4 Risks of anticoagulation
In an elderly population (262,611 patients ≥60 years free of dementia and 
stroke), it was observed that incident AF was associated with an increased risk of 
dementia independent of stroke, while anticoagulation therapy decreased the risk 
for dementia [70]. The association between AF and dementia is not well elucidated, 
but white matter lesions, silent brain infarcts, and microbleeds in the brain are more 
common in AF patients, and it is not clear whether anticoagulation might play a role 
in this decreased risk for dementia [71].
Patients with liver disease are at risk for increased bleeding with anticoagula-
tion therapy (but not increased thromboembolic events) [72]. However, NOAC 
therapy was shown in a clinical study (n = 39) to be safe and effective in cirrhosis 
patients [73].
Warfarin is teratogenic and should not be administered to pregnant women or 
women of childbearing potential without a clear understanding that they must not 
get pregnant while taking this drug [74].
6. Emergency anticoagulation and emergency anticoagulation reversal
NOAC anticoagulation offers advantages over VKA anticoagulation but also 
poses new challenges in the management of emergency situations. Emergency 
thrombolysis for treatment of ischemic stroke requires that the coagulation 
system be intact and, for this reason, is contraindicated in patients taking NOAC 
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drugs, unless the agent is completely reversed before [75]. Prothrombin time 
and other laboratory tests are often faster and easier to accomplish with VKA 
therapy than NOAC in emergencies. For major bleeding events, rapid reversal 
of anticoagulation may be required which is likewise easier with VKA; however, 
reversing VKA agents such as warfarin may still take hours. Among the NOAC 
options, only dabigatran has a reversal agent, while the reversal agents for the 
other NOAC medications are in development.
7. Evidence from clinical trials
The NOAC medications and warfarin have been the subject of large published 
clinical trials, but head-to-head studies among the NOACs have not yet been carried 
out, and attempts to analyze data across trials have been challenged by differences 
in study methodologies, the AF populations evaluated, definitions (stroke, AF, 
major bleeding, and so on), and composite endpoints [76]. A meta-analysis (n = 17 
studies) comparing rivaroxaban, dabigatran, and warfarin in real-world settings 
found that rivaroxaban was similar to warfarin in terms of the risks for major bleed-
ing, myocardial infarction, and all-cause mortality; rivaroxaban was associated 
with a lower risk for stroke or systemic thromboembolism compared to warfarin; 
however, rivaroxaban had a higher risk for gastrointestinal bleeding than warfarin. 
Compared to dabigatran, rivaroxaban had similar risks for stroke and systemic 
thromboembolism and myocardial infarction, but the risks for major bleeding, gas-
trointestinal bleeding, and all-cause mortality were higher with rivaroxaban than 
dabigatran [77]. A retrospective study found that rivaroxaban and apixaban elevate 
the INR to levels above the high cutoff for normal (84.2% of rivaroxaban and 78.3% 
of apixaban with rivaroxaban significantly higher than apixaban, p < 0.001); 
however the clinical implications for these elevated INR values are not known [78].
A retrospective study of 1365 geriatric patients with head trauma found that 
NOAC therapy was a safer alternative than warfarin, although warfarin and NOACs 
were associated with similar mortality rates. NOAC patients had a lower rate of intra-
cranial hemorrhage progression [79]. A retrospective database study of nonvalvular 
AF patients newly started on rivaroxaban, apixaban, or warfarin matched 11,411 riva-
roxaban users to 11,411 warfarin patients and reported that the risk of ischemic stroke 
or intracranial hemorrhage was significantly lower in the rivaroxaban patients than 
in the warfarin patients. The study further matched 4083 apixaban patients to 4083 
warfarin patients and found the combined endpoint (ischemic stroke or intracranial 
hemorrhage) was nonsignificantly reduced by apixaban versus warfarin. Apixaban 
reduced the risk of intracranial hemorrhage (hazard ratio 0.38, 95% confidence 
interval, 0.17–0.88) compared to warfarin, but the risk of ischemic stroke was nonsig-
nificantly increased by apixaban versus warfarin (hazard ratio 1.13, 95% confidence 
interval, 0.49–2.63). The study did not compare rivaroxaban to apixaban [80].
In a study of 962 consecutive TAVR patients prescribed with NOAC (n = 326) or 
VKA therapy (n = 636) after surgery, the composite study endpoint were all-cause 
mortality, myocardial infarction, and any cerebrovascular event. After 1 year of 
follow-up from TAVR, the composite endpoint occurred in 21.2% of NOAC and 
15.0% of VKA patients. Rates of bleeding and all-cause mortality were similar, but 
NOACs had a higher rate of ischemic events than VKA therapy [81]. In a systematic 
review of anticoagulation therapy in AF patients with valvular heart disease and 
bioprosthetic heart valves, edoxaban 30 mg was associated with the least rate of 
major bleeding compared to rivaroxaban, VKA, and other similar agents. Overall, 
NOAC medications were more effective in this population than warfarin, and 
NOACs were similar with the exception of edoxaban and major bleeding rates [82].
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Evidence from clinical trials shows promise but does not yet provide clinicians 
with a complete picture. For example, patients with moderate to severe mitral ste-
nosis or those with a mechanical heart valve are both at elevated risk from throm-
boembolism and typically excluded from head-to-head clinical trials that compare 
VKAs to specific NOACs. There are also patient groups who have been included in 
some, but not other trials, for example, patients who had a previous heart valve 
surgery (but not a mechanical valve) were excluded from RE-LY but included in 
ROCKET-AF, ΑRISTOTLE, and ENGAGE-AF. Patients with AF and a mechanical 
heart valve are routinely excluded from most head-to-head trials on anticoagula-
tion. Thus, there are gaps in the evidence as to which types of anticoagulation 
treatments are most effective in specific populations.
8. Clinical considerations for oral anticoagulants
Although it is well known that anticoagulation therapy can help prevent stroke 
in AF patients at risk for thromboembolic events, only about half of the indicated 
patients actually are prescribed with therapy [83]. There is an inverse relationship 
between antiplatelet prescription and non-prescription of anticoagulation therapy. 
However, antiplatelet therapy is not as effective as anticoagulation medications for 
stroke prevention [84]. When prescribing anticoagulation therapy, the clinician 
must evaluate several factors: the indications for anticoagulation therapy, individual 
patient characteristics, whether or not the patient is taking other medications, 
patient preferences (if any), clinician and institutional preferences, and cost [14]. 
When antiplatelet therapy is combined with anticoagulation, the risk for bleeding 
increases [14]. Among patients with nonvalvular AF, those with heart failure and/
or left-ventricular dysfunction have higher rates of bleeding and stroke/systemic 
embolism. Although some large trials of NOACs have included such patients, there 
have been no specific studies to investigate the safety of such drugs in these popula-
tions [85], and there is little evidence to guide prescribing choices.
Comorbidities must be considered when selecting the optimal anticoagulation 
regimen for a specific patient. Hepatic disease may increase the patient’s risk for 
bleeding and impairs hepatic drug metabolism and clearance. In NOAC trials, 
patients with liver disease were excluded, so there is a paucity of evidence about 
how to use NOAC therapy in this population. A retrospective database study from 
Korea (12,778 warfarin patients and 24,575 NOAC patients) found NOACs reduced 
the risk for ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, 
major bleeding, and all-cause death compared to warfarin. In the 13% of this 
study population with active liver disease, there was a lower rate for the composite 
endpoint (all endpoints above) for NOAC than warfarin [86].
Renal failure, common in AF patients, has an inflammatory pathophysiology 
and puts patients at risk for both thromboembolitic events and bleeding [87]. 
Since NOACs are cleared by the kidneys, renal failure has an adverse effect on 
NOAC pharmacokinetics but not on warfarin. However, warfarin likewise can 
interact with other drugs including drugs taken by patients managing kidney 
disorders [88]. A retrospective database study in Germany, RELOAD, compared 
outcomes of nonvalvular AF patients with compromised renal function tak-
ing either rivaroxaban or phenprocoumon (VKA therapy) and found that for 
patients with no evidence of cancer, rivaroxaban was associated with a lower rate 
of ischemic stroke and intracranial hemorrhage compared to phenprocoumon 
[89]. Warfarin is also more commonly prescribed to nonvalvular AF patients on 
hemodialysis, and while no head-to-head clinical trials have compared warfarin to 
NOACs in this population, dialysis patients are sometimes prescribed with NOAC 
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therapy. The preference for NOACs in the hemodialysis population may be due 
to several concerns: it is difficult to maintain warfarin at INR in the therapeutic 
range, warfarin may calcify vasculature, and dialysis patients have an elevated risk 
of intracranial hemorrhage. Hemodialysis patients are challenging for anticoagu-
lation, because they often are multimorbid, have extensive antibiotic exposure, 
and may have vitamin K deficiency. Adherence can also be especially problematic 
in the hemodialysis population [90].
The role of anticoagulation in cancer patients becomes complex as many cancer 
patients are at increased bleeding risk and may be taking antiplatelet agents and 
nonsteroidal anti-inflammatory drugs, have renal impairment, or be on chemo-
therapy. Many chemotherapeutic agents increase the patient’s risk of arterial and 
venous thrombosis, and chemotherapy that induces thrombocytopenia may elevate 
bleeding risks [91]. There is also the risk that anticoagulants may interact with 
chemotherapeutic agents or supportive-care drugs. Many chemotherapeutic regi-
mens (cisplatin, melphalan, cyclophosphamide) and some monoclonal antibodies 
increase the risk of nonvalvular AF. Cancer patients with AF have an increased risk 
for thromboembolism [92]. There is only limited knowledge of the risk of ischemic 
stroke attributable to cancer, and many risk assessment tools do not incorporate 
cancer. Further, cancer is not just one disease, and there may be important clinical 
variations with respect to the type of cancer, AF risk, and risk of thromboembolism 
and stroke [93].
Patient factors may also influence prescribing choices. Patient adherence must 
be considered in long-term anticoagulation therapy; the continuously adherent rate 
is under 45% for those newly diagnosed AF patients prescribed with some form 
of anticoagulation therapy [94]. Patient education may play a role in improving 
adherence. In a study of 339 adults on anticoagulation treatment for nonvalvular 
AF, participants evidenced moderate knowledge about AF but had a more limited 
understanding of anticoagulation and stroke [95]. Thus, better educational efforts 
may be helpful. Culture and ethnicity may also be a consideration when making pre-
scribing determinations. In a multinational survey of 937 adults on anticoagulation 
treatment for nonvalvular AF, national differences emerged such that US patients 
perceived AF as a serious condition, whereas the Japanese were less concerned about 
AF, but both were quite concerned about stroke risks. French patients preferred the 
physician to select AF therapy, while German, US, and Canadian patients preferred 
to be involved in therapeutic choices [96]. A cross-sectional survey of 226 physi-
cian specialists in Bulgaria also reports that 68% of patients who have an indication 
for anticoagulation therapy preferred a shared decision-making approach, and 
only 19% wanted the physician to make all anticoagulation therapy choices [97]. 
Improved understanding about the risk of stroke, the nature of stroke, and anticoag-
ulation treatment may improve adherence and empower patients in their own care.
Women taking warfarin have a greater risk of stroke/embolism than men, but 
this sex difference is not maintained for all of the NOACs [98]. Moreover, there is 
some evidence that with NOACs, women have less risk of major bleeding than men. 
The differences have been discussed in the literature and do not seem to apply to 
anticoagulation effectiveness [99]. Further studies are needed, but it appears that 
NOAC drugs may have some sex-based differences that at this time seem clinically 
unimportant.
9. Device-based approaches
Some patients have a relative or absolute contraindication to anticoagulation 
therapy. Device-based approaches may be important options for these patients. 
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It exceeds the scope of this chapter to describe these devices, their implantation, 
and results in detail, but a brief introduction is offered. Direct closure of the LAA 
via a minimally invasive surgical procedure is well established. It is a safe, effec-
tive procedure that can generally be performed in 30–40 min. Initially, the LAA 
was closed utilizing an endoscopic stapler, but more recently a minimally invasive 
LAA surgical clip is used (AtriClip, AtriCure, Inc., Cincinnati, Ohio, USA). The 
clip offers complete closure immediately, and no postoperative anticoagulation is 
needed.
A device implanted under fluoroscopic control into the orifice of the LAA 
by transseptal puncture may also be used (Watchman, Boston Scientific, Inc., 
Boston, Massachusetts, USA). This device has a high leak rate, and the US Food 
and Drug Administration requires postoperative anticoagulation for several 
weeks after implantation. Five-year outcomes from two large randomized 
clinical trials (PREVAIL and PROTECT AF) found that LAA closure with the 
WATCHMAN device offered stroke prevention in patients with nonvalvular AF 
comparable to that of warfarin with additional reductions in major bleeding and 
mortality [100].
In contrast to these is a suture-based occluding device (Lariat, SentreHEART, 
Redwood City, California, USA) that requires transseptal implantation. Unlike 
WATCHMAN, this device does in fact close the LAA, but in addition to a trans-
septal puncture, it requires access to the pericardium. A large randomized mul-
ticenter controlled trial is ongoing to determine the 30-day safety of this device 
and freedom from documented episodes of AF, atrial flutter, or atrial tachycardia 
>30 s at 12 months with a secondary composite endpoint of cardiovascular death 
or stroke [101].
10. Conclusions
New anticoagulation therapies are changing the paradigm of anticoagulation 
treatment for patients with certain forms of AF. This shift is further complicated by 
the fact that the definition and understanding of nonvalvular versus valvular AF are 
under scrutiny and evolving. Vitamin K antagonism (warfarin and other drugs) had 
been the standard of care for decades and still represents an important anticoagula-
tion option. The main drawbacks to VKA are the need for laboratory monitoring 
and strict therapy adherence to maintain anticoagulation efficacy plus the potential 
for drug-drug and food-drug interactions. A benefit for warfarin and other VKA 
treatments is the fact that the anticoagulation effect can be pharmacologically 
reversed. The arrival of the NOAC agents presents improved effectiveness in many 
key endpoints such as stroke prevention and similar or enhanced safety with respect 
to bleeding risks. There are four of these drugs (apixaban, dabigatran, edoxaban, 
and rivaroxaban), but as yet there are no head-to-head clinical trials among them 
for clinical guidance. Except for dabigatran, there are presently no reversal agents 
for these drugs. Clinicians must evaluate these anticoagulation approaches to make 
individualized decisions for patients. Further study is needed, particularly for 
specific subpopulations of AF patients: those with heart failure, implanted devices, 
renal compromise, and cancer.
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